Erasca, Inc., the San Diego-based oncology-focused biotechnology company listed on the NASDAQ Global Select Market, has disclosed a major public equity offering, pricing 31,428,572 shares of common stock at $17.50 per share through an underwriting agreement signed on July 13, 2026. The offering is expected to generate approximately $516.0 million in net proceeds for the company, rising to approximately $593.5 million if underwriters exercise their full overallotment option. With four of Wall Street's leading financial institutions serving as representatives of the underwriting syndicate, the capital raise represents a significant financing event that investors in the clinical-stage biotech sector are likely to monitor closely. The offering was expected to close on July 15, 2026, subject to the satisfaction of customary closing conditions.

Key Points

  • NASDAQ: ERAS
  • Erasca, Inc. priced a public offering of 31,428,572 shares of common stock at $17.50 per share on July 13, 2026
  • Expected net proceeds of approximately $516.0 million, or up to approximately $593.5 million if the underwriters' 30-day overallotment option for up to 4,714,285 additional shares is exercised in full
  • Investors should watch for confirmation that the offering closed on July 15, 2026, and for any company disclosures regarding the intended use of proceeds

Erasca Signs Underwriting Agreement With J.P. Morgan, Morgan Stanley, Jefferies, and Evercore

The underwriting agreement, dated July 13, 2026, was executed between Erasca, Inc. and four prominent financial institutions: J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC, and Evercore Group L.L.C., acting as representatives of the several underwriters named in the agreement. The involvement of these four major investment banks as joint representatives of the underwriting syndicate underscores the scale and structural complexity of the transaction. Each institution carried specific obligations and entitlements under the terms of the agreement as disclosed in the company's announcement.

Under the terms of the underwriting agreement, the underwriters agreed to purchase the 31,428,572 shares directly from Erasca at a price of $16.45 per share — representing the public offering price of $17.50 per share less underwriting discounts and commissions. The difference between the price paid by the underwriters and the price offered to the public reflects the standard underwriting spread associated with registered public equity offerings of this type. The filing states that the underwriting agreement contains customary representations, warranties, agreements, conditions to closing, indemnification obligations, and termination provisions.

Offering Price of $17.50 Per Share and Underwriter Discount Structure

Erasca set the public offering price at $17.50 per share for all 31,428,572 shares being sold in the transaction. The underwriters were entitled to purchase those shares at $16.45 per share, implying an underwriting discount of $1.05 per share. This spread is consistent with typical underwriting arrangements for registered public offerings in the biotechnology sector, and the terms were fully disclosed in the company's announcement filed with regulators on July 14, 2026.

The net proceeds to the company, after deducting underwriting discounts, commissions, and estimated offering expenses payable by Erasca, are expected to be approximately $516.0 million. The filing does not provide a breakdown of the specific components of estimated offering expenses, nor does it separately itemize the total underwriting discount across all shares. The company did not disclose the intended use of proceeds from this offering in the filing reviewed for this article, and investors seeking further detail on capital allocation may wish to consult the prospectus supplement and accompanying prospectus filed with regulators.

30-Day Overallotment Option Could Push Total Proceeds to $593.5 Million

In addition to the base offering of 31,428,572 shares, Erasca granted the underwriters a 30-day option to purchase up to 4,714,285 additional shares of common stock at the public offering price, less underwriting discounts and commissions. This overallotment option — commonly referred to as a "greenshoe" option in market parlance — is a standard feature of public equity offerings and allows underwriters to cover short positions that may arise in connection with the distribution of shares.

If the underwriters exercise this option in full within the 30-day window, the total net proceeds to Erasca would increase to approximately $593.5 million, according to the filing. The additional 4,714,285 shares, if fully issued, would bring the total potential share count from this offering to 36,142,857 shares. Whether and to what extent the underwriters exercise this option will depend on market conditions and demand dynamics following the offering's close, and no assurance of exercise was stated in the announcement.

Shelf Registration Statement Filed and Automatically Effective on July 13, 2026

The offering is being conducted pursuant to a shelf registration statement on Form S-3 filed by Erasca with regulators, bearing Registration Statement No. 333-297427, which the filing states automatically became effective upon filing on July 13, 2026. The use of an automatically effective shelf registration reflects Erasca's status as an emerging growth company that has satisfied the conditions necessary for this type of accelerated registration process, enabling the company to access capital markets in an efficient and timely manner.

The shares are being offered pursuant to a prospectus supplement and accompanying base prospectus filed in connection with the shelf registration statement. The filing also notes that the legal opinion regarding the legality of the issuance and sale of the common stock in the offering was provided by Latham & Watkins LLP and is attached as an exhibit to the disclosure. Latham & Watkins LLP also provided its consent, which was included within that same legal opinion exhibit. These are standard procedural elements of a registered public securities offering.

Erasca's Emerging Growth Company Status Under Securities Laws

The disclosure confirms that Erasca, Inc. qualifies as an emerging growth company as defined under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934. This classification carries specific regulatory implications, including certain reduced disclosure obligations and the ability to utilize extended transition periods for compliance with new or revised financial accounting standards, though the filing indicates that Erasca has not elected to use that extended transition period.

Emerging growth company status is relevant for investors because it can affect the level of financial and operational disclosure required of the company in certain regulatory filings. Erasca is incorporated in Delaware and maintains its principal executive offices at 3115 Merryfield Row, Suite 300, San Diego, California 92121. The company's common stock carries a par value of $0.0001 per share and is listed on the NASDAQ Global Select Market under the ticker symbol ERAS.

Expected Closing Date of July 15, 2026 and Customary Conditions

The filing states that the offering was expected to close on July 15, 2026, two days after the underwriting agreement was signed and the announcement was made public. The closing was stated to be subject to the satisfaction of customary closing conditions, which is standard language in registered underwritten public offerings. These conditions typically encompass legal opinions, the delivery of required documentation, and the absence of material adverse changes, though the specific conditions were not individually enumerated in the disclosure reviewed for this article.

The short window between the signing of the underwriting agreement on July 13, 2026 and the expected closing date of July 15, 2026 reflects the streamlined nature of a registered direct offering made pursuant to an effective shelf registration statement. The company issued two separate press releases on July 13, 2026 — one announcing the commencement of the offering and one announcing the pricing — copies of which were attached as exhibits to the announcement. The immediate share price impact was not clear from available public information.

Representations, Warranties, and Indemnification Provisions in the Underwriting Agreement

The underwriting agreement, as described in the filing, includes customary representations and warranties made by Erasca to the underwriters, as well as reciprocal obligations between the parties. The filing explicitly notes that the representations, warranties, and covenants in the underwriting agreement were made solely for the purposes of that agreement, as of specific dates, and for the exclusive benefit of the contracting parties. Investors are cautioned that these provisions are not intended to establish facts for the benefit of third parties, including public shareholders.

The agreement also includes indemnification obligations for both the company and the underwriters covering liabilities that may arise under the Securities Act of 1933, as amended. Additionally, the filing notes that the description of the underwriting agreement provided in the disclosure is not complete and is qualified in its entirety by reference to the full text of the underwriting agreement, a copy of which was filed as Exhibit 1.1 to the announcement. Investors seeking the complete terms of the agreement are directed to that exhibit.

Forward-Looking Statements and Risk Factors Highlighted by Erasca

Erasca included a standard forward-looking statements caution in its announcement, noting that statements that are not historical facts — including expectations regarding the completion of the offering and the expected net proceeds — are forward-looking in nature and subject to material risks and uncertainties. The company specifically identified market conditions and the satisfaction of customary closing conditions as factors that could cause actual results to differ materially from those described in the announcement.

The filing also directs investors to risks and uncertainties described in Erasca's Annual Report for the fiscal year ended December 31, 2025, and in any subsequent filings, particularly under the heading "Risk Factors." The company stated that it undertakes no obligation to update forward-looking statements to reflect events or circumstances arising after the date of the announcement. The forward-looking statements caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, a standard legal protection for companies making projections about future events.

Latham & Watkins LLP Provides Legal Opinion on Share Issuance Legality

Law firm Latham & Watkins LLP was retained by Erasca to provide a legal opinion on the legality of the issuance and sale of common stock in connection with the offering. This opinion, attached as Exhibit 5.1 to the announcement, is a standard regulatory requirement for registered public offerings and affirms that the shares being issued are legally authorized, validly issued, fully paid, and non-assessable. The consent of Latham & Watkins LLP was incorporated within the same exhibit, as is customary in such transactions.

The announcement was signed on behalf of Erasca, Inc. by Ebun Garner, the company's Chief Legal Officer, as the duly authorized signatory. The filing was dated July 14, 2026, one day after the underwriting agreement was executed and the two press releases were issued. The filing lists a total of five exhibits, including the underwriting agreement, the Latham & Watkins legal opinion and consent, the two press releases, and a Cover Page Interactive Data File embedded within the Inline XBRL document.